Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk
Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk
复制标题
DOI:
10.1093/eurheartj/ehl198
复制
发表时间:
2006-09-01
影响因子:
39.3
通讯作者:
Avogaro, Angelo
中科院分区:
文献类型:
--
作者:
Fadini, Gian Paolo;Vigili de Kreutzenberg, Saula;Avogaro, Angelo
Aims Circulating progenitor cells are believed to participate in cardiovascular (CV) homeostasis and their exhaustion has been linked to CV damage. As general agreement on their characterization is lacking, this work was carried out to assess the relationships between different antigenic profiles of progenitor cells and CV risk, with special regard to metabolic syndrome (MetSyn).Methods and results CD34, CD133, and KDR were used to quantify circulating progenitors in 214 subjects at different levels of CV risk. In a cross-analysis of six different cell subtypes (CD34(+), CD133(+), CD34(+)CD133(+), CD34(+)KDR(+), CD133(+)KDR(+), and CD34(+)CD133(+)KDR(+)), CD34(+) progenitors showed the best correlation with CV parameters and risk estimates. Components of the MetSyn were all characterized by reduction of CD34(+) cells and acted synergistically in decreasing CD34(+) cell count. Moreover, CD34(+) cell count demonstrated a high performance in detecting high CV risk.Conclusion These data demonstrate that CD34 identifies progenitor cells linked to CV risk, showing a close negative correlation between CD34(+) cells and CV risk, as well as a synergic detrimental effect of clustered metabolic components. Progenitor cell count may be used as a surrogate marker of CV risk, whereas extensive antigenic characterization may not be useful for this purpose.